OrbiMed’s ARS Pharmaceuticals SPRY Stock Holding History

OrbiMed’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.4M	Hold	8,288,510	–	–	1.23%	23
2026 Q1	$66.6M	Hold	8,288,510	–	–	1.32%	21
2025 Q4	$96.6M	Hold	8,288,510	–	–	1.97%	14
2025 Q3	$83.3M	Hold	8,288,510	–	–	1.96%	15
2025 Q2	$145M	Hold	8,288,510	–	–	3.61%	7
2025 Q1	$104M	Hold	8,288,510	–	–	2.49%	11
2024 Q4	$87.4M	Hold	8,288,510	–	–	1.8%	16
2024 Q3	$120M	Sell	8,288,510 -952,377	-10%	-$11.3M	2.18%	11
2024 Q2	$78.6M	Hold	9,240,887	–	–	1.55%	17
2024 Q1	$94.4M	Hold	9,240,887	–	–	1.73%	15
2023 Q4	$50.6M	Hold	9,240,887	–	–	1.01%	34
2023 Q3	$34.9M	Buy	9,240,887 +500,000	+6%	+$3.28M	0.74%	50
2023 Q2	$58.6M	Hold	8,740,887	–	–	1.06%	36
2023 Q1	$56.9M	Hold	8,740,887	–	–	1.12%	29
2022 Q4	$74.6M	Hold	8,740,887	–	–	1.43%	24
2022 Q3	$46.2M	Hold	8,740,887	–	–	0.86%	44
2022 Q2	$37.1M	Hold	8,740,887	–	–	0.67%	47
2022 Q1	$30.7M	Hold	8,740,887	–	–	0.5%	53
2021 Q4	$58.2M	Hold	8,740,887	–	–	0.75%	44
2021 Q3	$87.2M	Hold	8,740,887	–	–	0.96%	30
2021 Q2	$270M	Hold	8,740,887	–	–	2.73%	8
2021 Q1	$381M	Hold	8,740,887	–	–	3.57%	5
2020 Q4	$405M	Buy	+8,740,887	New	+$292M	3.54%	4

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed's SPRY Position: Q2 2026 in Review

OrbiMed held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 8,288,510 shares worth $66.4M. The position accounts for 1.23% of the portfolio, ranked #23.

OrbiMed first reported a position in SPRY in Q4 2020 and has held it in 23 quarters since. The position peaked at $405M in Q4 2020. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

OrbiMed held 8,288,510 shares of ARS Pharmaceuticals worth $66.4M as of Q2 2026.
OrbiMed left its ARS Pharmaceuticals share count unchanged in Q2 2026.
ARS Pharmaceuticals made up 1.23% of OrbiMed's portfolio in Q2 2026, its #23 holding.
OrbiMed first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
OrbiMed's ARS Pharmaceuticals position peaked at $405M in Q4 2020.
208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.